IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
View Top Employees from IO BiotechWebsite | http://www.iobiotech.com |
Revenue | $5 million |
Funding | $164.1 million |
Employees | 77 (73 on RocketReach) |
Founded | 2015 |
Address | 3 Ole Maaloes Vej, Copenhagen, Capital Region 2200, DK |
Phone | (452) 194-7856 |
Technologies |
JavaScript,
HTML,
PHP
+27 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Therapeutics |
Competitors | Agenus, Kite Pharma, Lengo Therapeutics, Selecta Biosciences, VGX Pharmaceuticals |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular IO Biotech employee's phone or email?
The IO Biotech annual revenue was $5 million in 2024.
73 people are employed at IO Biotech.
IO Biotech is based in Copenhagen, Capital Region.
The NAICS codes for IO Biotech are [54, 541714, 54171, 541, 5417].
The SIC codes for IO Biotech are [873, 87].